Several months back, a Biosimilar focused subsidiary of a Global Pharma had appointed Aagami to help out-license their Market ready Denosumab Biosimil...
Published : 19 Jan 2024
Read MoreWe are pleased to announce that Aagami has received contract extension from its Japan and US based client. Client is a nose to brain [NtoB]...
Published : 10 Jan 2024
Read MoreHappy with the delivery of the first Assignment, our US based client has now appointed Aagami for Acquisition/Partnering for their Patented s...
Published : 12 Dec 2023
Read MoreContinuing with its annual tradition, Aagami completed an action packed and productive Bio Europe in Munich (Nov 6-8, 2023). This time Aagami and...
Published : 14 Nov 2023
Read MoreJP Morgan Healthcare (JPM) week is an annual pilgrimage for Aagami and hence the team is already geared up for participation including Biotech Showcas...
Published : 22 Oct 2023
Read MoreA US based Innovator has appointed Aagami for evaluation of his Intellectual Property of two patent families and the underlying technology. The o...
Published : 27 Aug 2023
Read MoreAagami has a new client. This time it is a new subsidiary of an existing client from New York. The new client is focused on understanding the rol...
Published : 21 Aug 2023
Read MoreWe are glad to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2023 (November ...
Published : 17 Aug 2023
Read MoreThe end of July 2023 saw another reputed Global Pharma appoint Aagami for finding partner for ready to commercialize Denosumab Biosimilar in...
Published : 21 Jul 2023
Read MoreAagami are glad to announce that a Japan and US based Biotech has appointed Aagami to support fundraising and partnering of their portfolio of in...
Published : 10 Jul 2023
Read More